| Trial ID: | L1205 |
| Source ID: | NCT02966717
|
| Associated Drug: |
Rituximab
|
| Title: |
Rituximab Combined With MSCs in the Treatment of PNS (3-4 Stage of CKD)
|
| Acronym: |
CKD
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Renal Insufficiency, Chronic|Nephrotic Syndrome
|
| Interventions: |
DRUG: Rituximab|DRUG: conventional therapy|DRUG: Mesenchymal stem cells
|
| Outcome Measures: |
Primary: The change of serum creatinine elevation, The serum creatine elevation should be tested for at least 4 times, as follows, before treatment, 4 weeks after treatment, 8 weeks after treatment, 12 weeks after treatment., 4 weeks, 8 weeks, 12 weeks|The percentage of end-stage renal disease or death., The percentage of end-stage renal disease or death should be less than 60%., 3 years |
|
| Sponsor/Collaborators: |
Sponsor: Zhujiang Hospital
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
116
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2016-08
|
| Completion Date: |
2021-10
|
| Results First Posted: |
|
| Last Update Posted: |
2016-11-22
|
| Locations: |
Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, 510282, China
|
| URL: |
https://clinicaltrials.gov/show/NCT02966717
|
